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Macrophages have a central role in innate immunity, but they also play a part in the coordination of metabolic inflammation linked to metabolic diseases, including obesity and T2D 1, 2 . As obesity progresses, the expansion of AT coincides with the recruitment of macrophages, along with other types of immune cell. Specifically, resident macrophages switch into a metabolically activated state and initiate the recruitment of pro-inflammatory macrophages, collectively referred to as AT macrophages (ATMs), particularly in visceral fat [3] [4] [5] [6] [7] [8] [9] [10] . In both humans and mice with obesity, ATMs are considered to be a major source of inflammatory chemokines, such as C-C motif ligand-2 (CCL2, also known as monocyte chemoattractant protein-1, MCP-1) 11 , and cytokines, such as interleukin (IL)-6 (ref. 12 ) and tumor necrosis factor (TNF)-α 13 . The resulting state of low-grade metabolic inflammation, referred to as metaflammation 14 , interferes with AT expansion and metabolism related to lipid and glucose homeostasis. Concomitantly, AT-derived lipids and inflammatory mediators accumulate in peripheral tissues, such as the liver and muscle, and this is a crucial determinant for the development of insulin resistance, T2D, and associated metabolic disorders such as hepatic steatosis.
Despite advances in our understanding of the physiological and cellular events that trigger inflammatory signaling linked to AT dysregulation and ATM activation in obesity and T2D, our understanding of the underlying control mechanisms at the genomic and epigenomic levels is currently limited. Studies using cultured mouse macrophages have revealed an intrinsic relationship of transcription factor (TF) binding (cistromes), chromatin modifications (epigenomes), and gene expression (transcriptomes), both under nonstimulated conditions and in response to inflammatory signals such as lipopolysaccharide (LPS), an agonist of toll-like receptor (TLR) 4 (refs. 15-17) . These genomic studies identified a key role of lineage-determining 'pioneer' TFs, such as purine-rich (PU)-box transcription factor PU.1 and CCAAT/enhancer-binding proteins (C/EBPs), in the establishment of macrophage-specific enhancers 18, 19 . They further revealed insights into the role of signal-regulated TFs, such as members of the activator protein-1 (AP-1), interferon-response factor (IRF), and nuclear factor (NF)-κB families, in the rapid transcriptional response to inflammatory signals 15, 19, 20 .
To modulate the chromatin landscape and thus transcription in macrophages, TFs need to cooperate with co-regulators. Inflammatory gene activation during the transition from an inactive to an active chromatin state involves a co-repressor to co-activator switch, which, along with changes in histone modifications, triggers transcriptional initiation and elongation 15, 20, 21 . Notably, the perceived passive role of co-regulators ('being recruited by TFs') probably limits our appreciation of the regulatory impact that these co-regulators may have, which becomes important in light of disease-associated alterations. Therefore, it remains to be explored which of the many candidate co-regulators crucially modulates macrophage activation, particularly in the context of obesity-associated metabolic inflammation. Furthermore, it remains to be addressed whether and how metabolicdisease status affects the expression and function of co-regulators.
Among the most promising candidates currently to fulfill such a role in macrophage activation is a fundamental co-repressor complex that contains histone deacetylase 3 (HDAC3), as well as the core subunits GPS2; nuclear receptor co-repressor NCOR (encoded by NCOR1); silencing mediator of retinoid and thyroid hormone receptors SMRT (encoded by NCOR2); and transducing beta-like proteins TBL1 (encoded by TBL1X) and TBLR1 (encoded by TBLXR1) (refs. 22-25) . Initial studies in vitro revealed that this complex controls anti-inflammatory pathways, including nuclear receptor transrepression in macrophages [26] [27] [28] , in hepatocytes 29 , and in adipocytes 30, 31 . However, macrophage-specific and adipocyte-specific Ncor1 KO mice display an unexpected anti-inflammatory phenotype, as compared to wild-type (WT) mice, such as reduced AT inflammation and improved insulin sensitivity, upon diet-induced obesity 32, 33 . Although the relevance of these paradoxical phenotypes to the obese condition in humans has yet to be addressed, they raise the possibility that subunits other than NCOR are crucial determinants of the antiinflammatory role of the complex.
Here we address these issues and describe the unique dysregulation of GPS2, but not of any of the other complex-core subunits, in the ATMs of human subjects with obesity and T2D. By generating and characterizing macrophage-specific and adipocyte-specific Gps2 KO mice, along with carrying out bone marrow transplantation (BMT) experiments in mice with obesity (ob/ob or diet-induced obesity), and by performing genomic and epigenomic profiling, as well as humancorrelation analyses, we provide evidence that the anti-inflammatory GPS2 pathway required for proper insulin sensitivity is conserved in mice and humans. Furthermore, our study uncovers a hitherto unrecognized epigenomic disease mechanism that explains how the inappropriate function of a GPS2-containing co-repressor complex causes an increase in signal responsiveness of macrophage activation upon metabolic stress, which thereby further accelerates the progression of obesity-associated inflammation toward insulin resistance and T2D. Our findings imply that strategies that aim to restore GPS2 pathways in the ATMs of subjects with T2D may be of therapeutic value.
RESULTS

Relationship of GPS2 expression with T2D in humans
Given the suspected nonredundant roles of different co-repressor complex subunits in the control of macrophage inflammation linked to AT dysfunction and T2D, we analyzed whether the mRNA expression levels of these different subunits were correlated with the inflammatory and diabetic status of human subjects from three distinct populations ( Fig. 1a and Supplementary Table 1) . We focused on the analysis of ATMs isolated from the stromal vascular fraction (SVF). Population 1 (P1) was composed of subjects without obesity (n = 5; body mass index (BMI), 27 ± 0.5) versus with obesity (n = 21; BMI, 47.6 ± 1.4); population 2 (P2) consisted of subjects with obesity but without diabetes (n = 11; BMI, 43 ± 1.4) versus with both obesity and diabetes (n = 14; BMI, 42 ± 1.7); and population 3 (P3) consisted of subjects with neither obesity nor diabetes (n = 8) versus those without obesity but with diabetes (n = 16) (matched BMI, 29 ± 0.9).
We observed that in P1, the expression of GPS2 and HDAC3, but not of other subunits, was significantly (P < 0.001) lower in CD14 + -selected visceral AT (VAT) macrophages from subjects with obesity than in those from subjects without obesity (Fig. 1b and Supplementary  Fig. 1a,b) . Of note, subjects with diabetes had lower GPS2 and HDAC3 expression than did controls without diabetes in visceral ATMs from P2 and subcutaneous AT (SAT) from P3 (Fig. 1c,d) .
To investigate the relationship between the expression of GPS2 (and genes encoding the other core subunits) and inflammatory status, we determined the expression of chemokine CCL2 ( Supplementary  Fig. 1c,d ) and analyzed correlations in P2 and P3 (Supplementary Table 2 ). The analysis revealed that GPS2 levels were negatively correlated with CCL2 levels in populations both with (visceral ATMs, P2) and without (SAT, P3) obesity (Fig. 1e,f) .
The unique role of GPS2 in the context of T2D in subjects from both P2 and P3 subjects became evident through the analysis of the percentage of glycated hemoglobin (HbA1c), a glycemic parameter of diabetes severity, in correlation with the mRNA expression levels of the various subunits (Fig. 1g,h and Supplementary Table 3 ). The analysis revealed that the expression of GPS2 only, and not of the remaining subunit-encoding genes, was associated with diabetic status.
To decipher the possible causal relationship between GPS2 expression and macrophage activation, we conducted loss-of-function and gain-of-function studies ex vivo in CD14 + -selected ATMs ( Fig. 1i and Supplementary Fig. 1e,f) . GPS2 overexpression in the VAT ATMs of subjects with obesity (i.e., ATMs from a high-grade inflammatory environment) repressed-as compared to GFP overexpression-expression of the pro-inflammatory chemokine (CCL2 and IL8) genes and cytokine genes (IL1B, IL6, and TNF) (Fig. 1i) . On the contrary, RNA interference (RNAi)-mediated GPS2 depletion in the SAT ATMs of subjects without obesity (i.e., ATMs from a lowgrade inflammatory environment) was associated with a higher level, as compared to control siRNA treatment, of CCL2 and IL8 mRNA expression. By contrast, there was no change in IL1B and IL6 expression (Fig. 1i) . We further depleted GPS2 using small interfering (si) RNA in human monocyte-derived macrophages (HMDMs derived from healthy donors) under basal (nonstimulated) conditions, and determined changes in gene expression using microarray ( Fig. 1j and  Supplementary Fig. 1g) . The approach revealed a pro-inflammatory gene expression signature linked to major TLR and chemokine pathways, which was higher upon the depletion of GPS2, as compared to treatment with control siRNA. The human macrophage GPS2 signature was confirmed by RT-qPCR, a process that also identified CXCL8 (also known as IL8) as a major cytokine gene under the control of GPS2 ( Fig. 1j and Supplementary Fig. 1g,h) .
Collectively, these data suggest that dysregulation of GPS2 expression and function in human macrophages, particular in ATMs, could be causally related to AT inflammation in humans with obesity and diabetes.
Gps2 KO macrophages are pro-inflammatory and signal sensitized To investigate the macrophage function of GPS2 in vivo, we generated myeloid-specific Gps2 KO mice in the C57BL/6 background (LysMCre-Gps2 flox/flox ), hereafter referred to as MKO mice ( Supplementary  Fig. 2a ). GPS2 was efficiently removed at the mRNA and protein levels in bone marrow-derived macrophages (BMDMs) and in thioglycollate-elicited peritoneal macrophages (TEPMs) of MKO mice ( Fig. 2a and Supplementary Fig. 2b ). GPS2 depletion did not alter the expression of other complex-subunit genes in macrophages, and Gps2 expression was unaffected in other tissues examined ( Fig. 2a and Supplementary Fig. 2b,c) .
Given the diversity of various macrophage populations 34 , we investigated GPS2-regulated transcriptomes in BMDMs, TEPMs, and the AT SVF. We first analyzed gene expression in differentiated but nonstimulated BMDMs from MKO mice, relative to WT mice, using microarrays (Fig. 2b) . Of the annotated genes, approximately 500 genes were upregulated upon the removal of GPS2. Pathway analysis revealed the enrichment of pro-inflammatory signaling pathways in MKO versus WT BMDMs (Supplementary Fig. 2d) . We confirmed the microarray results for selected signature genes using RT-qPCR in BMDMs (Supplementary Fig. 2e ) and TEPMs (Supplementary Fig. 2f ). In agreement with the human data, chemokine genes such as Ccl2 and Ccl7 were among the top-ranking regulated genes in both types of MKO macrophages, as compared to those in WT mice.
Next, we performed bioinformatics analysis and found that the proinflammatory GPS2 signature, obtained in nonstimulated TEPMs, substantially overlaps with the LPS-induced TLR4 pathway that is characteristic of pro-inflammatory M1-type macrophage activation (Supplementary Fig. 2g ). To explore this further, we treated both BMDMs and TEPMs from WT mice and MKO mice for 6 h with LPS, and quantified gene expression by RT-qPCR (Fig. 2c,d ). We observed GPS2  CCL2  CCL5  CCL7  CXCL1  CXCL2  IL1B  IL6  CCL4  CXCL8  CCL6  TNF   P1  P2  P3  P4  P5  P6   8   6   4 2 0 mRNA fold change *** ** ** siControl siGPS2 The analysis of pro-inflammatory gene expression upon adenovirus-mediated GPS2 overexpression in CD14 + SVF cells isolated from the VAT of subjects with obesity (top; n = 5 different donors) and upon siRNA-mediated GPS2 depletion in CD14 + SVF cells isolated from the SAT of healthy subjects (bottom; n = 8 different donors). (j) Heat map of the upregulated genes in siGPS2-depleted HMDMs, as determined by microarray (top), and RT-qPCR confirmation of the siGPS2-depletion-induced upregulated genes in HMDMs (bottom; n = 6 different healthy donors). All mRNA expression levels were presented as relative to subjects without obesity or diabetes, Ad-GFP or siControl groups. Correlations were assessed by nonparametric Spearman's test. All data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, except where otherwise stated, versus nonobese, nondiabetic, siControl or AdGFP control groups, by Student's t test.
npg an enhanced LPS response of Ccl2 and Ccl7 expression both in MKO BMDMs and TEPMs, whereas the cytokine genes Il1b and Il6 were enhanced only in MKO TEPMs, as compared to WT cells. We also observed a sensitized LPS response (as compared to WT cells) upon the adenovirus-mediated short hairpin RNA (shRNA) depletion of GPS2 in the RAW264.7 macrophage cell line (hereafter referred to as RAW cells) (Supplementary Fig. 2h ). On the contrary, ectopic overexpression of GPS2 in RAW cells suppressed LPS induction of the same genes, as compared to control cells overexpressing GFP (Supplementary Fig. 2i ). Given the higher LPS-sensitivity of GPS2-deficient macrophages in vitro, we also investigated consequences in vivo using a mouse model of LPS-induced endotoxemia. Geneexpression analysis of TEPMs from WT and MKO mice injected with LPS (1 mg/kg) confirmed that the pro-inflammatory LPS response in vivo (after 16 h) was exacerbated in MKO mice relative to WT mice ( Supplementary Fig. 2j ). Finally, we asked whether metabolic activation was similarly affected by the removal of GPS2 from macrophages. Because the TLR4 pathway, in particular, orchestrates obesity-linked metabolic inflammation by sensing an abundance of saturated fatty acids 5 , we treated TEPMs from WT and MKO mice for 24 h with palmitate (C16:0) and observed elevated expression of pro-inflammatory signature genes in GPS2-deficient versus WT macrophages (Fig. 2e) . To address the question under physiological conditions in AT, we analyzed gene expression in the SVF of epididymal white AT (epiWAT) of WT and MKO mice fed with a low-fat diet (LFD) (Fig. 2f) . The results confirmed the elevated expression of GPS2 signature genes in MKO versus WT macrophages in an environment enriched in saturated fatty acids (Fig. 2e,f) .
Taken together, these data suggest a dual anti-inflammatory role of GPS2 in (i) the repression of gene activation in nonstimulated macrophages, and in (ii) the enhancement of pro-inflammatory responses by sensitizing macrophages to metabolic-stress signals.
Epigenome alterations in GPS2-deficient macrophages To define the chromatin occupancy (cistrome) of GPS2 in relation to the chromatin landscape (epigenome), we performed chromatinimmunoprecipitation-coupled genomic sequencing (ChIP-seq) in the BMDMs of WT versus MKO mice. Analysis of the genomic distribution of tag counts (peaks) revealed that approximately 50% of the GPS2-binding sites mapped to promoters (proximal to the transcription start site, TSS) and enhancers (intergenic regions, distal to the TSS) (Fig. 3a,b and Supplementary Fig. 3a-c) . Comparative analysis of the cistrome and the transcriptome in WT and MKO macrophages revealed GPS2 peaks at the promoters and enhancers of signature genes (Fig. 3c) . We further uncovered that quantitative changes of H3K27ac (marking active enhancers and promoters 34 ) were positively correlated with transcriptome regulation by GPS2 (Fig. 3d) ; this is indicative of transcriptional derepression or activation. For example, in GPS2-deficient macrophages, H3K27 acetylation was higher at the promoter (P) and enhancers (E) of the GPS2-sensitive Ccl2 gene locus, as validated by ChIP-RT-qPCR ( Fig. 3e-h ). By contrast, at the GPS2-resistant Tnf locus, H3K27 acetylation was not higher, which is consistent with no effect of GPS2 removal on Tnf expression 
npg
( Fig. 3c ,f-h). Related changes were observed for the promoterspecific H3K4me3 mark ( Fig. 3e-g ).
To investigate whether GPS2 co-localizes with the co-repressor complex, we compared the cistrome characteristics of GPS2 to those previously reported for NCOR, SMRT and HDAC3 in BMDMs 26, 35 . The analysis revealed an extensive overlap at the promoters and enhancers, with 6,867 sites to be co-occupied by all three subunits ( Supplementary Fig. 3d ), as exemplified by the Ccl2 locus ( Supplementary Fig. 3e ). We confirmed results by ChIP-RT-qPCR and further demonstrated that LPS activation induced the release of all subunits from distinct promoter and enhancer regions controlling Ccl2 expression (Supplementary Fig. 3f ).
We next tested the functional requirement of each core subunit for Ccl2 expression in RAW cells, and we found that shRNA-mediated depletion of SMRT or GPS2 enhanced LPS responses, as compared to shGFP control cells, whereas NCOR depletion had the opposite effect ( Supplementary Fig. 3g ). Moreover, GPS2 recruitment to the Ccl2 promoter and enhancers was abolished upon the depletion of SMRT but not that of NCOR (Fig. 3i) . To further test the relationship of GPS2 to SMRT or NCOR in repressing inflammatory gene expression, we depleted SMRT or NCOR in WT versus GPS2-deficient RAW cells generated with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system ( Supplementary Fig. 4a,b) . We observed that NCOR depletion (as compared to shGFP treatment) partially repressed Ccl2 elevation in Gps2 KO cells, whereas SMRT depletion did not further increase the elevated Ccl2 expression in Gps2 KO cells, in both basal and LPS-stimulated conditions ( Supplementary Fig. 4c ). This phenotype was confirmed in TEPMs from WT and MKO mice (Supplementary Fig. 4c) .
The above data indicated that GPS2 is functionally linked to SMRT but not to NCOR, an implication that is consistent with the opposite inflammatory phenotypes of GPS2 and NCOR-deficient macrophages 33 . Because the anti-inflammatory Ncor1 KO phenotype was attributed to the derepression of liver X-receptor (LXR, encoded by Nr1h2 and Nr1h3)-regulated genes (including Abca1, Scd1, Scd2, Fasn, Fads2, and Elovl5) linked to omega-3 fatty acid synthesis 33 , we investigated whether these genes were regulated in GPS2-deficient macrophages. In Gps2 MKO mice, as compared to WT mice, none of the genes had elevated expression in either basal TEPMs or LXR agonist (GW3965)-treated TEPMs (Supplementary Fig. 4d) . Similarly, the expression of these genes remained unchanged after GPS2 or SMRT depletion in RAW cells, as compared to shGFP treatment, whereas NCOR depletion induced the expression of Abca1 (Supplementary Fig. 4e) . Notably, the different functions of the complex subunits were not due to differential chromatin recruitment, given that all subunits were present at the Abca1 enhancer and promoter, here also co-localized with LXR ( Supplementary Fig. 4f ). Consistently with the lack of gene regulation, chromatin marks (i) ChIP-RT-qPCR analysis of GPS2 recruitment to the Ccl2 locus upon lentivirusshRNA-mediated depletion of GFP, NCOR, SMRT, and GPS2 in RAW cells. IgG and nonenhancer region C were used as controls for antibody and unspecific control gene, respectively. One-way ANOVA, followed by Tukey's test (n = 3). All data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 versus WT or lenti-shGFP groups.
were not changed at the Abca1 promoter and enhancers in MKO, as opposed to WT, BMDMs.
To further dissect the role of possible GPS2 subcomplexes, we investigated the relationship of GPS2 to HDAC3, the major histone deacetylase of the complex that directly associates with NCOR and SMRT 23 . Although HDAC3 protein levels were not altered in Gps2 MKO BMDMs, as compared to WT cells (Supplementary Fig. 5a ), deacetylase activity was slightly reduced in GPS2-deficient BMDMs and in GPS2-depleted RAW cells (Supplementary Fig. 5b ). For comparison, NCOR depletion strongly reduced HDAC3 activity by more than 70%, whereas SMRT depletion had no effects. These data suggested that NCOR, but not SMRT, is required as an activating co-factor for HDAC3 in macrophages, which is consistent with the overlapping anti-inflammatory phenotypes of the respective macrophage-specific KO mice 33, 35, 36 and with independent evidence from liver 37 . Because the data also suggested that GPS2 partly cooperates with HDAC3 in macrophages, we compared published Hdac3 KO transcriptome signatures from BMDMs 35, 36 to the Gps2 MKO signature, and we identified a number of common, upregulated genes in the respective KO mice, as compared to WT mice ( Supplementary  Fig. 5c ). We more closely investigated Ptgs1, a major HDAC3 target gene 36 that may be regulated by nuclear receptors but not by LPSinduced TLR4 activation. Indeed, GPS2 co-occupied a Ptgs1 enhancer, as did NCOR, SMRT and HDAC3, and the knockdown of GPS2, NCOR, SMRT or HDAC3 in RAW cells caused a comparable upregulation of Ptgs1 expression, as compared to shGFP-treated cells (Supplementary Fig. 5d ), which suggests that all of these subunits are functionally required for the repression of Ptgs1.
We conclude from these data that GPS2 mainly cooperates with SMRT to repress pro-inflammatory gene expression, whereas NCOR repression of LXR-regulated metabolic gene expression, linked to anti-inflammatory omega-3 fatty acid synthesis, is independent of GPS2 and SMRT.
AP-1 (c-Jun) is a direct target of GPS2
Given that GPS2 is found at most enhancers of regulated genes, it is likely to cooperate with numerous TFs to regulate macrophage inflammation. To identify candidates, we explored the GPS2-TF network using different approaches. De novo motif analysis ( Fig. 4a and Supplementary  Fig. 5e ) predicted that GPS2-bound genomic regions were specifically enriched for motifs recognized by lineage-specifying TFs, such as PU.1 and C/EBPs, consistent with the role of these factors in establishing macrophage-specific enhancers 15 . Among the motifs recognized by proinflammatory-signal-regulated TFs, the AP-1 and IRF motifs were most abundantly found in GPS2-bound regions. This suggests that GPS2 represses pro-inflammatory gene expression in part by targeting these factors. By contrast, NF-κB motifs and nuclear receptor half-site motifs were only poorly enriched at GPS2-bound regions.
To confirm the cistromic data, we immunoprecipitated GPS2 from nuclear extracts of WT and MKO BMDMs and subjected the precipitated protein-DNA complexes to an in vitro TF-interaction assay (Fig. 4b) , thereby identifying AP-1 factors as the most abundant interaction partners of GPS2, relative to other factors identified from the motif analysis (Fig. 4a,b and Supplementary Fig. 5e ). We then co-transfected HEK293 cells with HA-GPS2 and a representative collection of Flag-tagged TFs, and after immunoprecipitating the ; n = 6 in palmitate group) (f). n.s., nonsignificant. One-way ANOVA followed by Tukey's test. All mRNA levels were presented as relative to WT control or vehicle groups. All data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001.
npg cellular extracts with a Flag antibody, we identified the JUN protooncogene c-Jun as a strong GPS2-interacting partner ( Fig. 4c and Supplementary Fig. 5f ). Whereas interactions with other TFs that we tested were comparatively weak or absent (Fig. 4c) , GPS2 interacted strongly with the pioneer factor PU.1. Notably, the GPS2 and c-Jun binding sites 38 overlap extensively at the genome-wide level (Fig. 4d) and co-occupy enhancers at the Ccl2 locus (Fig. 4d) . The particular requirement of c-Jun for GPS2-dependent Ccl2 repression was confirmed upon RNAi depletion in WT and MKO TEPMs (Supplementary Fig. 5g ). Complementarily, we depleted or overexpressed GPS2 in BMDMs from macrophage-specific Jun KO mice and analyzed Ccl2 expression in response to LPS or palmitate treatment (Fig. 4e,f and Supplementary Fig. 5h,i) . Under both treatment conditions, GPS2-depletion-induced Ccl2 elevation was attenuated in Jun KO BMDMs, as compared to WT BMDMs (Fig. 4e) . Overexpression of GPS2 in Jun KO BMDMs, however, failed to inhibit LPS and palmitate responses above the level of inhibition seen in WT BMDMs (Fig. 4f) . Related data from TEPMs further confirmed these findings ( Supplementary Fig. 5h,i) . Collectively, these data identify the c-Jun component of AP-1 as a candidate GPS2 target for the repression of Ccl2 transcription.
GPS2-deficiency promotes obesity-linked insulin resistance
To further dissect the relationship between the inappropriate expression of GPS2 in macrophages, AT dysfunction, inflammation, and insulin resistance, we subjected WT mice and MKO mice to 60% high-fat diet (HFD) versus LFD feeding for up to 12 weeks (Fig. 5a and Supplementary Fig. 6a ). During the course of a 12-week HFDfeeding period, Gps2 mRNA expression levels decreased gradually in the F4/80 + ATM fraction from epiWAT of WT mice ( Supplementary  Fig. 6a) . In a manner consistent with the human data, GPS2 dysregulation in mouse AT was correlated with CD11c + macrophage infiltration and Ccl2 expression (Supplementary Fig. 6a,b) . Although the removal of GPS2 from macrophages did not change body-weight gain (Fig. 5b) , macrophage infiltration was enhanced in the epiWAT of MKO mice relative to that of WT mice (Fig. 5c,d) . Specifically, the elevation of the F4/80 + CD11b + ATM fraction in MKO mice was due to higher numbers of both CD11c + and CD206 + pro-inflammatory macrophages than that in WT mice (Fig. 5d) . Transcriptome profiling of epiWAT ATMs, followed by pathway analysis, confirmed that GPS2 removal provoked an enhanced pro-inflammatory response after 12 weeks of HFD feeding, which was verified by RT-qPCR ( Fig. 5e and  Supplementary Fig. 6c ). All mRNA levels were presented as relative to the WT group. All data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 versus WT group by Student's t test.
npg Pro-inflammatory gene-signature changes were further substantiated by a kinetic RT-qPCR analysis of the HFD response in AT, demonstrating an elevated expression of GPS2 signature genes in both the epiWAT and the inguinal white AT (ingWAT) of MKO mice versus WT mice ( Fig. 5f and Supplementary Fig. 6d,e) . Consistently with the fact that visceral fat depots are often more inflamed than subcutaneous depots, the elevated pro-inflammatory signature in GPS2-deficient epiWAT was already evident after 4 weeks of HFD feeding. The ATM-derived inflammatory transcriptome alterations in MKO versus WT mice resulted in systemically elevated levels of the encoded gene products CCL2, IL-6 and TNF-α after HFD feeding (Fig. 5g) . Probably as a consequence of the inflammatory alterations, AT properties were changed in MKO mice, as indicated by smaller adipocyte size (Supplementary Fig. 6f ), higher expression of fibro-inflammatory and lipolytic genes (Supplementary Fig. 6g) , and higher basal lipolytic activity-indicated by more glycerol release from AT ( Supplementary Fig. 6h )-than those in WT mice. Consistently with the AT lipolysis change, MKO mice also had elevated circulating nonesterified free fatty acids (NEFA) levels (Supplementary Fig. 6h) . Correspondingly, liver weight and intrahepatic triglyceride (TG) content was higher in MKO mice than in WT mice, indicating worsening of the HFD-induced steatosis in MKO mice (Fig. 5h) . These metabolic changes were accompanied by substantially elevated macrophage infiltration (Supplementary Fig. 6i ) and expression of proinflammatory genes, including Ccl2 (Supplementary Fig. 6j ), in the livers of MKO, as compared to WT, mice after HFD feeding.
Given that inflammatory alterations may trigger insulin resistance, we further investigated glucose homeostasis in MKO versus WT mice (Fig. 5i) . We observed that both fasting and feeding bloodglucose levels were elevated in MKO mice, in conjunction with higher serum insulin levels. Analysis of the homeostatic model assessment of insulin resistance (HOMA-IR) index, an oral glucose-tolerance test (OGTT), and an insulin-tolerance test (ITT) all supported the progression of MKO mice to a state of greater insulin resistance, relative to WT mice, after 12 weeks of HFD feeding (Fig. 5i) . Elevated insulin resistance as a consequence of GPS2 dysfunction was confirmed at GPS2 expression and function in macrophages, and metabolic inflammation in the context of obesity and T2D. CoA, coactivators; HATs, histone acetyltransferases. All mRNA levels were presented as relative to C57BL/6 GFP or ob/ob GFP groups. All data are represented as mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001 versus C57BL/6 GFP or ob/ob GFP groups by Student's t test.
npg the intracellular level, given that AKT phosphorylation, a readout of intracellular insulin signaling, in epiWAT, muscle, and liver was reduced after in vivo insulin stimulation in MKO mice, as compared to WT mice (Fig. 5j) . Taken together, the results suggest that macrophage GPS2 has a crucial role in controlling metaflammatory responses and its consequences in the AT, as well as in controlling systemic responses that originate from AT under conditions of diet-induced obesity.
GPS2 overexpression improves glucose homeostasis in obese mice
To test the anti-inflammatory and potentially anti-diabetic function of GPS2 in vivo, we transplanted bone marrow cells overexpressing GFP, or Flag-tagged human GPS2, into freshly irradiated WT C57BL/6 or leptin-deficient mice (ob/ob). At 5 weeks after BMT, ob/ob mice were euthanized for analysis, whereas WT mice were fed with a HFD for 10 weeks (as outlined in Fig. 6a) . A modest overexpression of GPS2 was confirmed in F4/80 + macrophages in the epiWAT (Supplementary Fig. 7a,b) and in the livers of mice that received transplants (Supplementary Fig. 7c ). Expression analysis of epiWAT and F4/80 + ATMs from epiWAT revealed that Ccl2, Ccl7, Il1b, and Il6 mRNA levels in both GPS2 overexpression models were lower than those in the recipient mice transplanted with GFP-expressing bone marrow cells (Fig. 6b,c) . A similar expression pattern was observed in the ingWAT (Supplementary Fig. 7d,e) . This lower epiWAT inflammation was characterized by a lower ATM number in both models (Fig. 6d,e) . Of note, less inflammation was observed in the livers of mice overexpressing GPS2 (Supplementary Fig. 7f-h) , which accumulated fewer macrophages and lipids than did GFP control mice (Supplementary Fig. 7f,i,j) . Mice with obesity that overexpressed GPS2, as compared to control mice expressing GFP, displayed no evident change in their blood-glucose levels, whereas insulin levels were significantly (P < 0.001) changed; this, along with the HOMA-IR score, OGTT, and ITT, suggests that they were more insulin sensitive and glucose tolerant (Fig. 6f-i) .
In sum, these experiments suggest that increasing GPS2 levels in macrophages can counteract obesity-linked metabolic inflammation of AT, thereby helping to maintain systemic insulin sensitivity and prevent ectopic lipid partitioning in the liver (steatosis).
Loss of adipocyte GPS2 contributes to insulin resistance Given previous evidence that GPS2 controls, in part, related proinflammatory pathways in human adipocytes 30 and in the mouse 3T3-L1 adipocyte cell line 39 , we wanted to compare the relative contributions of macrophage GPS2 and adipocyte GPS2 to the abovedescribed AT alterations. We generated adipocyte-specific KO mice (referred to as AKO) by crossing the floxed GPS2 mice with mice expressing Cre under the control of adiponectin promoter (Adipoq-Cre). Gps2 mRNA and protein expression were significantly (P < 0.001) decreased in isolated adipocytes of epiWAT in AKO mice, compared to those in WT littermates, whereas Ncor1, Ncor2, and Hdac3 were not altered (Supplementary Fig. 8a ). WT and AKO mice were then subjected to a HFD for 12 weeks. Body weight remained unchanged, despite a slightly greater epiWAT and ingWAT mass in AKO versus WT mice (Supplementary Fig. 8b,c) . Histological analyses of the epiWAT and ingWAT revealed significantly (P < 0.001) enlarged average adipocyte size in AKO mice, relative to that in WT mice, after 12 weeks of HFD feeding ( Supplementary  Fig. 8d,e) , a difference probably driven by a higher partition of large adipocytes (>100 µm) and a decrease of smaller adipocytes (<100 µm) in AKO mice.
Gene-expression analysis of isolated adipocytes from the epiWAT of WT and AKO mice revealed higher expression of Ccl2, Ccl5, Ccl7, and Il6 in AKO mice, whereas Tnf was not changed (Supplementary  Fig. 8f) . A similar signature was observed in the epiWAT and ingWAT of AKO mice (Supplementary Fig. 8f) . Consistently with the geneexpression changes, systemic CCL2 protein concentration was higher in the serum of AKO mice (Supplementary Fig. 8g) . Furthermore, macrophage infiltration, including that of CD11c + and CD206 + macrophages, was greater in the epiWAT of AKO mice after HFD feeding than in that of WT mice fed the same diet (Supplementary Fig. 8h) .
Insulin-stimulated glucose uptake was substantially lower in AKO mice, which supports a local impairment of insulin sensitivity in AKO mice, relative to that in WT mice (Supplementary Fig. 8i) . Fasting blood-glucose levels were elevated in AKO mice, whereas serum insulin levels showed no difference. Accordingly, the HOMA-IR index revealed that the AKO mice were more insulin resistant than were WT mice (Supplementary Fig. 8j) . Lastly, an OGTT showed that AKO mice were less glucose tolerant than WT mice, whereas the ITT did not reveal significant changes (Supplementary Fig. 8j ). This indicated that the local AT insulin resistance observed in AKO mice had no major influence on systemic insulin sensitivity, within the limits of 12 weeks on a HFD.
In conclusion, the AKO data support the anti-inflammatory function of GPS2 in adipocytes, which directly influences AT insulin sensitivity, but also reveal some intriguing differences related to AT properties, lipid metabolism, and systemic insulin resistance between the respective AKO and MKO models.
DISCUSSION
Our study identifies the co-repressor GPS2 as an epigenomic component of metabolic macrophage activation in the context of obesity and T2D. The analysis of two novel macrophage-specific versus adipocyte-specific Gps2 KO mouse models, along with the study of human subjects with obesity and diabetes, suggests that the depletion or reduction of GPS2 promotes a pro-inflammatory gene-activation signature and sensitizes the responses of macrophages, including ATMs, toward metabolic signals. We additionally demonstrate that the overexpression of GPS2 in bone marrow cells of mice with obesity can improve insulin sensitivity and reduce inflammation, which might be of therapeutic significance. Overall, our findings point to a causal, and potentially reversible, relationship between inappropriate GPS2 expression and function, the extent of tissue inflammation, and systemic insulin resistance. The underlying mechanisms seem to be conserved between mice and humans, and they exemplify how the epigenome alterations in macrophages can shape the metabolic-disease environment during progression toward T2D (see our model in Fig. 6j) .
Given the mouse and human conservation of the identified GPS2 pathways, our study helps to better interpret the role of epigenetic mechanisms in human metabolic health and disease. For example, although obesity is commonly associated with risk factors for cardiovascular disease, including insulin resistance and T2D, some subjects with obesity who have a similar BMI do not develop metabolic and inflammatory abnormalities 40 . There are probably several molecular reasons that are responsible for such individual differences, but some could be related to epigenomic mechanisms, described here for macrophages and in other studies for adipocytes 30, 31, 39, 41 . Indeed, our HFD-fed Gps2 MKO mice develop metabolic alterations (fatty liver, glucose intolerance, and insulin resistance) more rapidly than WT mice, whereas no weight difference is observed. This phenotype is intriguingly comparable to the human situation of metabolically npg healthy versus unhealthy subjects with obesity. Although immune cells, including macrophages, are ultimately linked to the pathological alterations of AT during the manifestation of the inflamed obesity status, it is less clear how they maintain a pro-inflammatory status during the continued progression of obesity and diabetes. Closely linked epigenomic and transcriptional alterations have been proposed to have roles in the establishment of a 'metabolic memory' in AT, particularly in adipocytes 42 . Our findings point to a related 'inflammatory memory' in macrophages; decreased GPS2 expression in AT and ATMs in humans with obesity and diabetes therefore limits its anti-inflammatory capacity as disease progresses.
Our study uncovers a hitherto unrecognized epigenomic feature of co-repressors during the signal-dependent transcriptional activation linked to metaflammation. Comparative analysis of the GPS2 cistrome, epigenome and transcriptome revealed that GPS2 occupies H3K27ac-marked enhancers at regulated genes, which undergo epigenomic changes upon GPS2 removal. Derepression is not the only consequence of a loss of GPS2; the responses to acute (LPS) and metabolic (palmitate, HFD) signals were further enhanced. This is compatible with recent findings demonstrating that an increase in H3K27ac at enhancers opens the entrance for incoming TFs upon signaling 43 . Intriguingly, an epigenomic memory mechanism would explain how alterations in GPS2 levels modulate the activity of inducible inflammatory TFs, even in the absence of physical interactions between GPS2 and these TFs. Overall, the epigenomic and signalsensitizing functions of GPS2 in macrophages complement and go beyond the anti-inflammatory actions of GPS2 in hepatocytes 29 and in adipocytes described previously 31, 39, 42 . We therefore propose that obesity-mediated, GPS2-dependent epigenomic changes in human macrophages, including ATMs, establish an epigenomic memory that accelerates inflammatory responses to metabolic signals.
Our work helps to clarify the functions of other co-repressor complex subunits in vivo in relation to GPS2. Gps2 MKO mice are a relevant disease model for metaflammation, characterized by hallmarks that include (i) chronic elevated low-level inflammation under basic-or chow-diet conditions; (ii) accelerated AT inflammation and macrophage infiltration; and (iii) the development of systemic insulin resistance under diet-induced obesity conditions 14 . Therefore, the main function of GPS2 in macrophages is to act as an antiinflammatory co-repressor, which seems in sharp contrast to the reported pro-inflammatory roles of NCOR and HDAC3 in vivo.
Macrophage-specific Ncor1 KO mice display an anti-inflammatory phenotype with reduced AT inflammation and improved insulin sensitivity upon HFD feeding, probably due to the derepression of LXR pathways linked to the synthesis of omega-3 fatty acids 33 . Closer investigation in our MKO model and in RAW cells indicated that GPS2 has no major role in the repression of these pathways in macrophages, and that it provides possible alternative mechanisms. Although the comparative depletion of GPS2, SMRT and NCOR in RAW cells confirmed the opposing roles of GPS2 and SMRT relative to NCOR in controlling inflammatory transcription, among the LXR target genes, only Abca1 was upregulated upon NCOR depletion. Additionally, the removal of GPS2 or SMRT had no effect on any of the tested LXR target genes. This points to a unique role of ABCA1 in inflammation control, as recently suggested 44 , or at an intrinsic pro-inflammatory role of NCOR, as previously noted in mouse and human adipocytes 30, 32 .
It is also possible that the pro-inflammatory role of NCOR in macrophages is directly linked to HDAC3: macrophage-specific Hdac3 KO mice 35 ,36 display a pro-inflammatory phenotype characterized by decreased M1 (LPS/TLR4) and increased M2 (IL4) responses. Our analysis further revealed that NCOR, but not SMRT, is required for HDAC3 activity, consistently with the overlapping KO phenotypes. Notably, that SMRT cannot substitute for NCOR in acting as a cofactor for HDAC3 and in targeting specific TFs and enhancers has been earlier observed in liver 37 , and contrasts with the seemingly redundant function of these two related co-repressors in vitro. Similarly, the in vivo preference of GPS2 for SMRT over NCOR has not been obvious from studies in vitro 24, 25 , and thus is likely to involve additional interaction surfaces, post-translational modifications 45 or cellular cofactors. Overall, these data explain why two core subunits of the 'same' co-repressor complex-GPS2 versus NCOR-have opposite inflammatory KO phenotypes in macrophages. Our findings provide a conceptual framework proposing the functional (but not necessarily biochemical or genomic) separation of 'the co-repressor complex' into at least two sub-complexes with opposing activities in macrophages, one acting as an anti-inflammatory (GPS2-SMRT) and one as a pro-inflammatory (NCOR-HDAC3). This may offer pharmacological opportunities for the selective modulation of GPS2-dependent inflammatory pathways that avoids interfering with the metabolic-anti-inflammatory axis governed by NCOR-HDAC3.
By demonstrating the particular relationship of GPS2 to c-Jun (AP-1), our work provides additional clues for how the co-repressor complex functionally interacts with TFs. De novo prediction revealed AP-1 motifs to be the most frequent at GPS2-occupied enhancers; GPS2-associated AP-1 binding sites were enriched from macrophage nuclear extracts; knockdown experiments proved that c-Jun was required for Ccl2 repression by GPS2; and c-Jun strongly interacted with GPS2 in co-immunoprecipitations. Earlier work had elucidated in detail the essential role of c-Jun in TLR4 signaling 46 and Ccl2 regulation 47 . c-Jun is further suggested to interact with HDAC3 (ref. 48 ), SMRT and NCOR 27, 49, 50 , suggesting cooperative interactions with various subunits of the co-repressor complex, all of which may contribute to the function of SMRT and NCOR in repressing AP-1-dependent inflammatory-gene expression.
The above considerations help to explain why GPS2, along with the entire co-repressor complex, is also found at the enhancers of genes whose transcription is apparently not affected by the removal of GPS2. In line with the emerging concept of enhancer hot spots 51, 52 , the presence of the GPS2 co-repressor complex, along with other co-regulators and multiple TFs, at key inflammatory enhancers before activation ensures fast and reversible transcriptional responses to different signaling inputs triggered by different metabolic and inflammatory alterations. Given that such alterations are typically associated with T2D, it is of therapeutic interest that GPS2 is one of the first examples of an epigenomic modifier whose expression and function in macrophages is influenced by the metaflammatory disease status itself. This suggests therapeutic possibilities for delaying or even reversing metaflammation-linked T2D through the restoration of GPS2 expression and its function within co-repressor subcomplexes by, for example, administering epigenomic drugs or by the pharmacological modulation of the c-Jun-GPS2-SMRT interface.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Gene Expression Omnibus (GEO): Gene expression and ChIP-seq data have been deposited under the accession codes GSE66774 (ChIP-seq) and GSE66874 (gene expression).
npg ONLINE METHODS
Human tissue samples. AT biopsies were obtained from different subject cohorts admitted to the Labriboisière, Pitié-salepetrière and Geoffroy SaintHilaire hospitals (Paris, France), as detailed in Supplementary Table 1 . The study was conducted in accordance with the Helsinki Declaration and was registered in a public trial registry (Clinicaltrials.gov; NCT02368704 and NCT01655017). The Ethics Committee of CPP Ile-de-France approved the clinical investigations for all individuals, and written informed consent was obtained from all individuals. SAT and VAT samples from lean subjects were obtained after local surgery, and VAT from subjects with obesity was obtained after bariatric surgery. P1 consisted of CD14 + cells from SVF from the VAT of individuals with and without obesity. P2 consisted of CD14 + cells obtained from SVF from the VAT of individuals with obesity but no diabetes and the VAT of individuals with obesity and diabetes. P3 comprised SAT tissue from individuals with obesity and diabetes or with diabetes but without obesity. The clinical and anthropometric variables that were measured are shown in Supplementary Table 1, including sex, age, BMI (kg/m 2 ), total cholesterol (mmol/l), triglycerides (mmol/l), and HbA1c (in %).
CD14 + SVF cells containing ATMs were isolated, as previously described 4 . Subcutaneous and visceral (omental) AT from human subjects with and without obesity were digested using collagenase (Roche) and SVF cells were resuspended in endotoxin-free Dulbecco's Phosphate-Buffered Saline (DPBS) supplemented with 2% FCS (FCS) and 1 mM EDTA. CD14 + SVF cells were purified using magnetic beads (STEMCELL Technologies, 18058), according to the manufacturer's instructions. Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated FCS or immediately used for total RNA or protein extraction.
To obtain HMDMs, blood samples were received from healthy volunteer donors (Etablissement Français du Sang, Pitiè-salpêtrière Hospital). Human peripheral blood mononucleated cells (PBMCs) were isolated from enriched buffy coats by Ficoll density gradient centrifugation and purified using the Monocyte Isolation Kit II (Miltenyi Biotec, 130-091-153). PBMCs were differentiated into HMDMs in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% FCS and 100 ng/ml of macrophage colony-stimulating factor (M-CSF) (Miltenyi Biotec, 130-096-493) for 6 d.
RT-qPCR analysis. RNA was extracted from tissues or purified cells using the RNeasy RNA Mini Kit (Invitrogen). Complementary DNAs were synthesized using Superscript II reverse-transcriptase kit (Life Technologies). RT-qPCR was performed using the ABI Prism 7000 PCR system (Applied Biosystems). 18S and 36B4 (gene encoding acidic ribosomal phosphoprotein P0, also called RPLP0) were used for normalization to quantify relative mRNA expression levels. Relative changes in mRNA expression were calculated using the comparative cycle method (2 − Membranes were incubated with ECL western-blotting substrate (Pierce, 32106) and imaged by myECL Imager (ThermoFisher, 62236). Blots were semi-quantified using ImageJ software.
Transient transfection, RNAi, and adenoviral infection. We used human GPS2 siRNAs, as described previously 29 , and mouse GPS2 (M-063123, Dharmacon), c-Jun (L-043776, Dharmacon), and Rel A (P65) (L-040776, Dharmacon) siRNAs in our experiments. Luciferase siRNA (TGACAGAGCCAAACAAATG) was used as a negative control. 100 nM siRNAs, along with Lipofectamine 2000 (Life Technologies), were used for the transfection of both human and mouse macrophages. For the adenovirus experiments, the ectopic GPS2-overexpressing adenovirus was as described previously 30 .
Human and mouse gene-expression microarray analysis. Briefly, total RNA from HMDMs transfected with control or GPS2 siRNA for 40 h, WT and MKO BMDMs in basal conditions (n = 3 per group), WT and MKO TEPMs treated with or without 10 ng/ml LPS for 6 h (n = 3 per group), and HFD-fed WT and MKO AT SVF F4/80 + cells (n = 4 per group) were extracted using RNA miniprep kit (Qiagen), according to the manufacturer's instructions. 250 ng of HMDM RNA, 50 ng of BMDM RNA, 50 ng of TEPM RNA, and 100 ng of SVF F4/80 + cells RNA were used according to the manufacturer's instructions, to obtain biotin-labeled cDNAs.
HMDMs. Illumina Human HT-12 v3.0 Expression BeadChips (containing 48,000 annotated probes for 28,688 coded transcripts) was used. BMDMs. Affymetrix mouse gene 1.1 ST plate (with 24,582 well-established annotations) was used. RNA samples from replicates were subjected to analysis. The target synthesis and hybridization were performed at the Bioinformatics and Expression Analysis core facility (BEA, Karolinska Institutet, Huddinge, Sweden), according to the standardized protocol.
TEPMs and SVF F4/80 + cells. Illumina MouseRef-8 v2.0 Expression BeadChips (containing 25,600 annotated probes for 19,100 coded transcripts) was used.
To obtain the biotin-labeled cDNAs of all the samples for the Illumina microarrays, the Illumina RNA amplification kit (NuGEN, BiotinIL, Module) was used. BeadChips were read with an iScan Illumina scanner. Hybridization probe intensities were then detected using GenomeStudio. The q value is the adjusted P value for multiple testing using an optimized false-discovery rate (FDR) approach (as defined by J.D. Storey's method). The q value was provided by SAMr package under R statistical software. The differentially expressed genes were further annotated using WebGestalt with biological annotations from Gene Ontology and KEGG databases.
For the BMDMs and TEPMs, raw-intensity expression files (CEL files) were imported to R and Bioconductor using the Oligo 53 package. The same package was used for quantile normalization, background correction, and summarization by robust multichip average preprocessing (RMA). The normalized log 2 -transformed expression values were then imported to the Limma 54 package for differential-expression analysis by linear modeling. A paired design was used to remove the batch effect between the biological replicates. Furthermore, genes with low expression (less than the 95 th quantile of the negative-control probes on the Affymetrix chip) were removed. Genes with a P value of <0.05, after adjusting for multiple hypothesis testing using the FDR method, were defined as being differentially expressed. Hierarchical clustering of the gene expression in WT and MKO mice, was performed in R with the Hclust function using the ward.D2 method, and visualized employing the ggplot2 package 55 . Prior to hierarchical clustering, genes were standardized across the samples to a mean of zero and an s.d. of 1; z values were then used for clustering. Limma was also used for the analysis of the microarray data from the peritoneal macrophages.
Mice. Gps2 flox/flox mice were generated at Ozgene Pty, Ltd. (Bentley DC, Australia) using a targeting construct, which contained loxP sites flanking exons 2 and 5, followed by a FRT site and a neomycin cassette inserted between exons 5 and 6. The targeting vector was electroporated into C57BL/6 Bruce4 embryonic stem (ES) cells. The correctly recombined ES colony was then injected into C57BL/6 blastocysts. Male chimeras were mated with female C57BL/6 mice to get mice with a targeted Gps2 allele. The mice were crossbred with C57BL/6 flp-recombinase mice to remove the neomycin cassette to create heterozygous Gps2 flox/+ mice. The mice were then crossbred with C57BL/6 mice for nine generations before being bred with heterozygous Gps2 flox/+ mice to get the Gps2 flox/flox mice.
To generate myeloid-specific or adipocyte-specific Gps2 KO mice, Gps2 flox/flox mice were crossed with LysM-Cre mice (B6.129P2-Lyz2tm1(cre)Ifo/J; Jackson Laboratory stock no. 04781) or adiponectin-Cre mice (B6;FVB-Tg(Adipoq-Cre) 1Evdr/J; Jackson Laboratory stock no. 010803), respectively. KO mice were pipeline of EdgeR to identify potential differential binding sites 63, 64 . We used only tags from peaks that were identified at least twice from all the ChIP-seq experiments.
Generation of Gps2 KO RAW264.7 cells by CRISPR. The sgRNAs for Gps2 were designed on CRISPR gRNA design tool: Design 2.0. The following sequences of sgRNAs (sgRNA1: CACCGGCAAACGGCAGGGTGAGCCT and sgRNA2: CACCGGATGTGCCGGTGCAGAGCCC) were inserted into PX461 vector 65 (Addgene plasmid 48140) and sorted by FACS. The single-cell colonies were validated via sequencing for at least five separate T clones, and were further validated by western blot. PX461 empty-vector transfected and sorted single-cell clones were used as negative controls.
HDAC3 activity assay. HDAC3 activity was determined using a commercial kit (Active Motif, 56200) according to the manufacturer's instructions. Briefly, nuclear extracts were incubated with anti-HDAC3 (Santa Cruz, sc-11417) coupled to protein A beads for 2 h at 4 °C. Beads were washed five times with washing buffer and directly incubated with HDAC substrate. HDAC3 activity was determined using fluorescence-based measurement.
GPS2-interacting TF array. The GPS2-interacting TF array was performed according to the kit manufacturer's instructions (Signosis, FA-3001). Briefly, 20 µg of protein sample from WT or MKO BMDM nuclear extracts were incubated with a provided oligo mix (containing TF DNA binding-site sequences) for 1 h and then incubated with protein A/G magnetic beads with 2 µg GPS2 antibody for 1 h at 4 °C. The GPS2-bound oligos were eluted in an elution buffer at 98 °C for 10 min and were hybridized in a plate where the corresponding synthetic antisense oligos were bound. The bound biotin-labeled oligos were then detected with streptavidin-HRP and substrate.
Co-immunoprecipitation of GPS2 and candidate TFs. HEK293 (ATCC, CRL-1573) cells were co-transfected with pcDNA3-HA-GPS2 (WT or 61-94, deletion of the interaction site with SMRT and NCOR 25 ) and expression plasmids for the indicated Flag-tagged TFs. Flag-tagged SMRT (2-297) served as a positive control for comparison. Cells were lysed 48 h after transfection, and the lysate was incubated with anti-HA (BioLegend, 901513) or anti-Flag (Sigma-Aldrich, F7425) coupled to protein A magnetic beads for 3 h, at 4 °C (previously 15-µl beads were incubated with 2 µg of antibody for 2 h, at 4 °C). Beads were washed with lysis buffer five times and eluted at 98 °C for 10 min. The eluted sample was loaded in an acrylamide gel by following the western blot protocol, and blotted with anti-Flag or anti-HA. Whole-cell lysis was used as input. C/EBP plasmids were kindly provided by Susanne Mandrup (University of Southern Denmark, Denmark), and NF-κB plasmids were gifts from Karolien De Bosscher (University of Gent, Belgium. The remaining TF cDNAs were obtained from the Karolinska Institutet High Throughput Center (KHTC) and cloned into the pcDNA3.1-3XFlag-V5 expression vector.
Metabolic studies in mice. 7-8-week-old WT and MKO mice (n = 5-7 per experiment) were fed with a 60%-fat diet (HFD, Research Diets, D12492) or with a 10%-fat diet (LFD, Research Diets, D12450) for 4, 8, and 12 weeks. The 12-week HFD experiments were repeated three times independently. OGTT and ITT were performed before and after the HFD feeding. For insulinsignaling assays, WT and MKO mice were fasted for 6 h and then i.p. injected with 0.75 U/kg insulin. Mice were euthanized after 15 min, and liver, epididymal AT, and muscle were collected for western blot analysis. Lean tissue and fat mass were measured using an Echo Medical systems' EchoMRI 100 (Whole Body Composition Analyzers, EchoMRI, Houston, USA), according to the manufacturer's instructions.
Immunohistochemical and morphometric analyses. AT and liver tissue samples were fixed in 3% formaldehyde solution overnight and embedded in paraffin. Tissue slides were stained with H&E for the evaluation of the tissue morphology, following standardized protocols. AT and liver tissue macrophage infiltration was evaluated by immunohistochemistry (IHC) using a F4/80 antibody (AbD Setotec, MCA497R). Adipocyte size was measured by the diameters of the adipocytes in light-microscopy images (20×) of AT sections (n = 50 adipocytes per section, three sections per mouse, seven mice per group) and analyzed using ImageJ software. Experiments were done in a blinded manner.
FACS analysis of HFD mice AT SVF.
Purified adipose SVF cells were resuspended in FACS buffer and stained with indicated fluorescent isotopeconjugated antibodies for 30 min at 4 °C in the dark. The antibodies used for FACS included F4/80 (BM8; eBioscience, 25-4801-82, 1:100), CD11b (M1/70; eBioscience, 17-0112-82, 1:300), CD11c (N418; eBioscience, 48-0114-82, 1:100) and CD206 (C068C2; BioLegend, 141704, 1:50). Live/Dead fixable dead cell stain (Invitrogen, Paisley, UK) was used to discriminate between live and dead cells. The cells marked with the antibody were then washed three times with DPBS and fixed in 1% paraformaldehyde before analysis. Samples were analyzed in a LSRII cytometer (Becton Dickinson) using FACS Diva (BD Biosciences) and FlowJo (Tree Star) softwares.
Analysis of metabolic parameters. Blood glucose levels were measured using a glucometer (Accu-Chek Performa, Roche). Plasma insulin (Mercodia, 10-1247-01), CCL2 (R&D Systems, 855993), IL-6 (R&D Systems, 872791) and TNF-α (R&D Systems, 783567) concentrations were determined by ELISA. HOMA-IR in mice was calculated using the following equation: (fasting glucose concentration × fasting insulin concentration)/405. Plasma NEFA and glycerol release were measured using the colorimetric diagnostic kit, according to the manufacturer's instructions (Randox Laboratories). Liver TGs were extracted and measured with a colorimetric diagnostic kit, according to the manufacturer's instructions (WAKO diagnostics).
BMT and lentiviral infection. BMT was performed as previously described 66 . In brief, lentivirus expressing GFP (as control) or Flag-GPS2 were titered and used to transduce C57BL/6 WT or ob/ob BM cells. Cells were cultured for 24 h in transplantation media (RPMI + 10% FBS + 6 ng/ml IL-3, 10 ng/ml IL-6, and 10 ng/ml stem cell factor) and treated by spin infection with lentiviral supernatants (0.4 ml supernatant per 4 × 10 6 cells in the presence of polybrene) and centrifuged at 1,800g for 90 min. The spin infection was repeated 24 h later. After washing, the cells were used for BM transplantation into lethally irradiated WT recipient mice.
Immunofluorescence. Immunofluorescence analysis of AT was performed on paraffin-embedded sections of 10 ìm on poly-l-lysine-coated glass slides. Briefly, tissue sections were dewaxed through three consecutive incubations (5 min) in xylene and then rehydrated by three consecutive incubations (3 min) in 96-100% ethanol, followed by washes in de-ionized water. Sections were then incubated for 15 min at room temperature in 3% (v/v) hydrogen peroxide, followed by two washes in de-ionized water. Photo-bleaching with 5 min under UV lamp and Oil Red O emersion for 2 min were applied to quench auto-fluorescence. Sections were then blocked for 30 min with Tris-buffered saline (TBS) solution and 3% bovine serum albumin (w/v). Primary antibodies diluted in TBS + 1% (w/v) BSA were applied for 2 h at room temperature, slides were then washed in TBS + 0.1% (v/v) Tween20 three times for 5 min, and the secondary antibodies were applied for 1 h at room temperature in the dark. Slides were then washed in TBS + 0.1% (v/v) Tween20 three times for 5 min, slides were mounted with VectaShield mounting media with DAPI and sealed with a transparent lacquer before imaging.
Images were acquired on an Axiovert 200M microscope using appropriate filters. The following antibodies were used: anti-F4/80 (1:50 AT, Cl:A3-1, MCA497, AbD Serotec), anti-Flag (1:100 AT, F7425, Sigma-Aldrich), anti-Rat TRITCconjugated secondary antibody (A18870, ThermoFisher); anti-Rabbit FITCconjugated secondary antibody (F2765, Life Technologies). Secondary antibodies were applied at a dilution of 1:200. GFP and DAPI were imaged directly.
AT glucose-uptake analysis. Glucose uptake of [3H]-2-deoxyglucose was assayed, as described 67 . In brief, AT explants (ingWAT and epiWAT) were preincubated in the absence or presence of 100 nmol/l of insulin and 50 mmol/l of [3H]-2DG (NEN, Boston, Massachusetts, USA; specific activity 26.2 Ci/mmol). After 10 min of incubation, explants were washed in ice-cold Krebs Ringer HEPES (KRH) buffer to stop transport and washed an additional four times in the same buffer to remove unbound label. Explants were blotted, and then npg proteins were quantified to normalized. 3H radioactivity was determined by scintillation counting using a Minaxa Scintillation counter from Packard. Basal glucose uptake was taken as 2-deoxyglucose uptake in the absence of insulin.
Statistical analysis. All statistical tests were performed using GraphPad Prism 6.0b (GraphPad Software, Inc., La Jolla, CA), and all data are represented as mean ± s.e.m. Statistical tests were assessed after confirming that the data met appropriate assumptions (normality, homogenous variance, and independent sampling). Gaussian distribution was tested using the Kolmogorov-Smirnov test. Group comparisons were assessed with Student's t test to compare two groups, and one-way ANOVA test followed by Tukey's or Dunnett's post hoc test for multiple comparisons as appropriate. Human and mouse correlations were performed using Spearman's test. All statistical tests were two-tailed, and P < 0.05 was defined as significant. No statistical methods were used to predetermine sample size. No samples or animals were excluded from the analyses.
